Clinical trials: Breast Cancer, Metastatic Breast Cancer
Metastatic Breast Cancer
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial).
- Trial name
- HOPE-Focus (NCT06991946)
- Testing
- Liquid Biopsy, Archival Tumor DNA
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of HER2-CAR-T cell Infusion for advanced HER2 positive breast cancer.
- Trial name
- NCT02547961
- Testing
- HER-2-targeting CAR T Cells infusion
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
- Trial name
- DUAL-NK-BC (NCT07486089)
- Testing
- Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Metastatic Breast Cancer
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
By doing this study, researchers hope to learn the effectiveness of the combination of Lapatinib and RAD-001 for treating patients who have progressed on previous therapies.
- Trial name
- NCT01283789
- Testing
- Lapatinib and RAD-001
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Kansas Medical Center
Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site" of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into the blood stream (intravenous or "IV"). 1.
- Conditions
- Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03789097
- Testing
- Pembrolizumab, Flt3L, Radiation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Breast Cancer
Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine
This feasibility study will be conducted in order to provide proof of concept for the CanADVICE+® system comprising a smart phone app and a healthcare organization server side application based on Web 2 technologies.
- Trial name
- NCT02580396
- Testing
- CanADVICE+® (smart phone app)
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Breast Cancer
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
This study is a national, multicenter, prospective, non-interventional study in women with HR+/HER2- locally advanced or metastatic breast cancer (BC), for which a prior clinical decision to initiate ribociclib + endocrine…
- Trial name
- RosaLEE (NCT05697146)
- Testing
- ribociclib + ET
- Where
- 82 sites in France
- Volunteers
- 1,019 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Cancer
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.
- Trial name
- NCT04032080
- Testing
- Drug 1: LY3023414; Drug 2: Prexasertib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Metastatic Breast Cancer
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
The primary objective of the study is to study the pharmacokinetics of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.
- Trial name
- NCT04367090
- Testing
- Docetaxel, trastuzumab, Pyrotinib
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Metastatic Breast Cancer
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
- Trial name
- NCT01597388
- Testing
- AZD2014, Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Triple Negative Breast Cancer
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
This multicenter observational real-world study is planned to enroll 100 patients, divided into two cohorts: the triple-negative breast cancer (TNBC) cohort and the hormone receptor-positive/human epidermal growth factor receptor…
- Conditions
- Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Breast Cancer
- Trial name
- NCT07018427
- Testing
- Sacituzumab Govitecan Monotherapy or Combination Therapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Metastatic Triple-negative Breast Cancer (mTNBC)
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and…
- Trial name
- NCT07340424
- Testing
- 225Ac-TR2205 Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Xiaorong Sun
Metastasis Solid Tumors, Advanced Breast Cancer
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
This study includes single agent/combination dose exploration study and the phase II study. The primary purpose of the dose exploration study is to determine the maximum tolerated dose(MTD)/recommended phase II dose(RP2D) of…
- Trial name
- NCT04539496
- Testing
- XZP-3287, XZP-3287;Letrozole;Anastrozole;Fulvestrant
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Metastatic Breast Cancer, Metastatic Colorectal Cancer
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers
The proposed theory is based on combination of radiation therapy with usual targeted therapies capable of ADCC (Antibody-Dependant Cell Cytotoxicity).
- Conditions
- Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer
- Trial name
- IRAM (NCT03323424)
- Testing
- Systemic treatment + Stereotactic Body Radio-Therapy (SBRT), Systemic treatment
- Where
- 6 sites in France
- Sponsor
- Institut de Cancérologie de la Loire
Breast Cancer, Invasive Breast Cancer
Onvansertib + Paclitaxel In TNBC
This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body.
- Conditions
- Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer
- Trial name
- NCT05383196
- Testing
- Onvansertib, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Antonio Giordano, MD
Breast Tumors
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis
Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.
- Trial name
- DAISY (NCT04132960)
- Testing
- DS-8201a
- Where
- 15 sites in France
- Volunteers
- 186 people
- Sponsor
- UNICANCER
Metastatic Breast Cancer
HER2-positive Metastatic Breast Cancer in Kazakhstan
Planned study population consists of approximately 240 adult patients with HER2-positive mBC receiving anti-HER2 therapy in 12 oncological centers (in each center it is expected to recruit about 20 patients) in different regions…
- Trial name
- NCT07593196
- Where
- 12 sites in Kazakhstan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
This study was a multicenter, randomized, double-blind, placebo-controlled Phase III study to determine the efficacy and safety of treatment with Buparlisib plus Fulvestrant vs.
- Trial name
- BELLE-3 (NCT01633060)
- Testing
- Fulvestrant, BKM120
- Where
- 197 sites in United States, Argentina and 20 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05573555
- Testing
- ARV-471, Ribociclib
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.